Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Hubert Beaumont"'
Publikováno v:
Insights into Imaging, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Reader variability is intrinsic to radiologic oncology assessments, necessitating measures to enhance consistency and accuracy. RECIST 1.1 criteria play a crucial role in mitigating this variability by standardizing evaluations, aiming to es
Externí odkaz:
https://doaj.org/article/1c2e683edfe54f8fb214f3736ea85533
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
With the increasingly central role of imaging in medical diagnosis, understanding and monitoring radiological errors has become essential. In the field of oncology, the severity of the disease makes radiological error more visible, with both individu
Externí odkaz:
https://doaj.org/article/7f3e24af688544dcbd1631f2d51859f1
Autor:
Hubert Beaumont, Antoine Iannessi
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundIn lung clinical trials with imaging, blinded independent central review with double reads is recommended to reduce evaluation bias and the Response Evaluation Criteria In Solid Tumor (RECIST) is still widely used. We retrospectively analyz
Externí odkaz:
https://doaj.org/article/7241ce2d08b04138ad2cff74dcb8a500
Autor:
Hubert Beaumont, Nathalie Faye, Antoine Iannessi, Emmanuel Chamorey, Catherine Klifa, Chih‐Yi Hsieh
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 3112-3122 (2023)
Abstract Objective We compared therapeutic response of Varlitinib + Capecitabine (VC) versus Lapatinib + Capecitabine (LC) in patients with human epidermal growth factor receptor 2‐positive metastatic breast cancer after trastuzumab therapy by asse
Externí odkaz:
https://doaj.org/article/fa7098504ec84edd9305dabf24f34f2c
Autor:
Antoine Iannessi, Hubert Beaumont
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundIn clinical trials with imaging, Blinded Independent Central Review (BICR) with double reads ensures data blinding and reduces bias in drug evaluations. As double reads can cause discrepancies, evaluations require close monitoring which sub
Externí odkaz:
https://doaj.org/article/f4869ff386ba48628a64a04d0e8657a7
Publikováno v:
Insights into Imaging, Vol 12, Iss 1, Pp 1-9 (2021)
Abstract Response Evaluation Criteria In Solid Tumors (RECIST) is still the predominant criteria base for assessing tumor burden in oncology clinical trials. Despite several improvements that followed its first publication, RECIST continues to allow
Externí odkaz:
https://doaj.org/article/fcee1559cd6842969ab2f6cdc6fbd440
Publikováno v:
Insights into Imaging, Vol 12, Iss 1, Pp 1-3 (2021)
Abstract Artificial intelligence algorithms are booming in medicine, and the question of biases induced or perpetuated by these tools is a very important topic. There is a greater risk of these biases in radiology, which is now the primary diagnostic
Externí odkaz:
https://doaj.org/article/219bf8c5f4824b3ca88e17722ef97278
Autor:
Hubert Beaumont, Tracey L. Evans, Catherine Klifa, Ali Guermazi, Sae Rom Hong, Mustapha Chadjaa, Zsuzsanna Monostori
Publikováno v:
Cancer Imaging, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background In imaging-based clinical trials, it is common practice to perform double reads for each image, discrepant interpretations can result from these two different evaluations. In this study we analyzed discrepancies that occurred betw
Externí odkaz:
https://doaj.org/article/94ec747fbc7245c3a7522bfe9294c810
Publikováno v:
PLoS ONE, Vol 13, Iss 2, p e0192124 (2018)
The measure of body surface area (BSA) is a standard for planning optimal dosing in oncology. This index is derived from a model having questionable performances. In this study, we proposed measurement of BSA from whole body CT images (iBSA). We test
Externí odkaz:
https://doaj.org/article/ce5e2a0b0b4a42e4b74564eea915591b
Autor:
Emmanuel Chamorey, Antoine Iannessi, Chih-Yi Hsieh, Hubert Beaumont, Catherine Kliffa, Nathalie Faye
Publikováno v:
Cancer medicineREFERENCES.
Objective: We compared therapeutic response of Varlitinib + Capecitabine (VC) versus Lapatinib + Capecitabine (LC) in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab therapy by assessing chan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b707a0763ee0625d9ad496a8f94ca8f2
https://pubmed.ncbi.nlm.nih.gov/36098367
https://pubmed.ncbi.nlm.nih.gov/36098367